[HTML][HTML] GD2-CART01 for relapsed or refractory high-risk neuroblastoma
…, V Bertaina, M Sinibaldi, S Di Cecca… - … England Journal of …, 2023 - Mass Medical Soc
Background Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …
[HTML][HTML] SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best
…, S Terreri, C Quintarelli, F Pulvirenti, S Di Cecca… - Journal of clinical …, 2021 - Springer
Background Data on immune responses to SARS-CoV-2 in patients with Primary Antibody
Deficiencies (PAD) are limited to infected patients and to heterogeneous cohorts after …
Deficiencies (PAD) are limited to infected patients and to heterogeneous cohorts after …
[HTML][HTML] Safe and effective off-the-shelf immunotherapy based on CAR. CD123-NK cells for the treatment of acute myeloid leukaemia
…, DA Silvestris, M Sinibaldi, S Di Cecca… - Journal of Hematology & …, 2022 - Springer
Background Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes
in patients with relapsed/refractory disease, despite the improvements in intensive standard …
in patients with relapsed/refractory disease, despite the improvements in intensive standard …
Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives
GL Pira, S Di Cecca, M Montanari, L Moretta, F Manca - Blood Reviews, 2016 - Elsevier
Hemopoietic stem cell transplantation (HSCT) is a standard procedure for treatment of
malignant and non-malignant hematological diseases. HSCT donors include HLA-identical …
malignant and non-malignant hematological diseases. HSCT donors include HLA-identical …
[HTML][HTML] Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies
…, S Reddel, L Iaffaldano, M Pezzella, S Di Cecca… - Nature …, 2023 - nature.com
Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients
with B-cell malignancies not responding to conventional therapies. However, potentially …
with B-cell malignancies not responding to conventional therapies. However, potentially …
[HTML][HTML] B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies
…, S Terreri, E Piano Mortari, C Quintarelli, S Di Cecca… - Cells, 2021 - mdpi.com
Background: Patients with primary antibody deficiencies are at risk in the current COVID-19
pandemic due to their impaired response to infection and vaccination. Specifically, patients …
pandemic due to their impaired response to infection and vaccination. Specifically, patients …
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
…, M Guercio, Z Abbaszadeh, M Sinibaldi, S Di Cecca… - Leukemia, 2020 - nature.com
We developed an innovative and efficient, feeder-free culture method to genetically modify
and expand peripheral blood-derived NK cells with high proliferative capacity, while …
and expand peripheral blood-derived NK cells with high proliferative capacity, while …
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL
…, V Bertaina, M Sinibaldi, S Di Cecca… - Blood, The Journal …, 2023 - ashpublications.org
Autologous CD19-directed chimeric antigen receptor (CAR)-T cells have shown unprecedented
efficacy in children with relapsed/refractory B-cell precursor acute lymphoblastic …
efficacy in children with relapsed/refractory B-cell precursor acute lymphoblastic …
[HTML][HTML] CD28. OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T cells
M Guercio, D Orlando, S Di Cecca, M Sinibaldi… - …, 2021 - ncbi.nlm.nih.gov
The prognosis of many patients with chemotherapy-refractory or multiply relapsed CD30+
non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) still remains poor, and novel …
non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) still remains poor, and novel …
[HTML][HTML] Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR. CD19 T cell therapy in B-cell malignancies
…, S Manni, I Boffa, S Caruso, S Di Cecca… - Frontiers in …, 2021 - frontiersin.org
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in
patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non…
patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non…